Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025288 | 0.84 | HCRTR2 (0.41) | HCRTR2HCRTR1SSTR4SSTR1ACACB | |
| SCHEMBL10058619 | 0.84 | HCRTR2 (0.43) | HCRTR2HCRTR1SSTR4SSTR1ACACB | |
| SCHEMBL13969530 | 0.81 | MEN1 (0.41) | — | |
| SCHEMBL14546379 | 0.80 | IDO1 (0.41) | HCRTR2HCRTR1SSTR4 | |
| SCHEMBL12237062 | 0.77 | HCRTR2 (0.42) | HCRTR2HCRTR1SSTR4SSTR1ACACB | |
| SCHEMBL13627670 | 0.77 | SSTR4 (0.37) | HCRTR2HCRTR1SSTR4 | |
| SCHEMBL10058063 | 0.77 | MEN1 (0.42) | — | |
| SCHEMBL10058624 | 0.75 | SLC6A2 (0.42) | — | |
| SCHEMBL10058620 | 0.73 | GRIN1 (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL1178075 | 0.69 | SLC6A2 (0.52) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | HCRTR2 4803/4885HCRTR1 4390/4885SSTR4 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.